Antibody-Drug Conjugate

Preliminary phase 2 results from the REJOICE-Ovarian01 trial show raludotatug deruxtecan (R-DXd) demonstrates clinically significant response in recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The study observed a 50.5% objective response rate across all doses. The Phase 3 portion will evaluate a 5.6 mg/kg dose of R-DXd against chemotherapy. R-DXd, a CDH6-directed antibody drug conjugate, is being jointly developed by Daiichi Sankyo and Merck, highlighting collaborative efforts in oncology drug development due to high unmet needs in late stage ovarian cancer.

Daiichi Sankyo and Merck announced positive Phase 2 IDeate-Lung01 trial results for ifinatamab deruxtecan (I-DXd) in previously treated extensive-stage small cell lung cancer (ES-SCLC). I-DXd demonstrated a 48.2% objective response rate (ORR) in patients who had progressed after platinum-based chemotherapy, with a median duration of response of 5.3 months. Notably, a second-line subset achieved a 56.3% ORR. Discussions with regulatory authorities are underway. The safety profile was consistent with prior observations.